Literature DB >> 31387830

Fluorescence-guided bone resection: A histological analysis in medication-related osteonecrosis of the jaw.

Falk Wehrhan1, Manuel Weber2, Friedrich W Neukam2, Carol-Immanuel Geppert3, Marco Kesting2, Raimund H M Preidl4.   

Abstract

PURPOSE: Surgical treatment of medication-related osteonecrosis of the jaw (MRONJ) consists of necrotic bone removal followed by dense mucosal closure. Fluorescence-guided surgery has become a promising tool to intraoperatively distinguish between healthy and necrotic bone. Until now, there has been a lack of histopathological studies correlating the intraoperative fluorescence situation to histopathological analyses of the respective bone areas in order to further validate this method.
MATERIALS AND METHODS: Histopathological sections from intraoperatively detected fluorescence- and non-fluorescence-labeled bone were analyzed detecting osteocyte and collagen content, RANK(L) and TRAP expression as well as proportion of immature bone regeneration. Samples were compared with viable-looking bone areas according to the intraoperative clinical situation.
RESULTS: Staining revealed a significant decrease of osteocytes and collagen type-I fibers in necrotic, non-fluorescing areas compared to fluorescing bone (R/RGB [%]: 0.56 ± 0.38 (fluorescence positive) vs. 3.18 ± 2.22 (fluorescence negative), p = 0.041). Furthermore, the number of osteocytes was higher in fluorescing, clinically viable bone samples (cell/mm2: 151.26 ± 95.77 (fluorescence positive) vs. 0.56 ± 0.38 (fluorescence negative), p = 0.028). Additionally, the amount of immature bone was substantially increased in luminescent jaw bone (proportion of red [%]: 6.78 ± 7.00 (fluorescence positive) vs. 2.24 ± 1.36 (fluorescence negative), p = 0.442). RANK(L) and TRAP expression did not differ between the investigated areas, resembling a generalized decrease in osteocyte-osteoclast function all over the jaw (RANK(L) -positive cells per mm2: 8.97 ± 7.85 (fluorescence positive) vs. 7.76 ± 6.41 (fluorescence negative), p = 0.793; TRAP-positive cells per mm2: 0.36 ± 0.38 (fluorescence positive) vs. 0.33 ± 0.41 (fluorescence negative), p = 0.887).
CONCLUSION: Intraoperative fluorescence-guided surgery might be more precise in identifying and resecting the necrotic bone compared to previous indicators like bone bleeding, which could be useful to further improve surgical therapy in MRONJ patients.
Copyright © 2019 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  BRONJ; Bisphosphonate; Bone fluorescence; Doxycycline; MRONJ

Year:  2019        PMID: 31387830     DOI: 10.1016/j.jcms.2019.07.012

Source DB:  PubMed          Journal:  J Craniomaxillofac Surg        ISSN: 1010-5182            Impact factor:   2.078


  4 in total

1.  Fluorescence-guided surgery for osteoradionecrosis of the jaw: a retrospective study.

Authors:  Suad Aljohani; Riham Fliefel; Teresa Franziska Brunner; Aristeidis Chronopoulos; Nada Binmadi; Sven Otto
Journal:  J Int Med Res       Date:  2022-06       Impact factor: 1.573

2.  Differences between auto-fluorescence and tetracycline-fluorescence in medication-related osteonecrosis of the jaw-a preclinical proof of concept study in the mini-pig.

Authors:  Oliver Ristow; Dirk Nehrbass; Stephan Zeiter; Daniel Arens; Julius Moratin; Christoph Pautke; Jürgen Hoffmann; Christian Freudlsperger; Sven Otto
Journal:  Clin Oral Investig       Date:  2020-05-22       Impact factor: 3.573

Review 3.  The Therapeutic Effectiveness Using Fluorescence-Guided Surgery for MRONJ.

Authors:  Hongyuan Huang; Ning Zhao; Qingxiang Li; Qiao Qiao; Jianya Zhang; Chuanbin Guo; Yuxing Guo
Journal:  Biomed Res Int       Date:  2022-09-17       Impact factor: 3.246

4.  Perspective on optical imaging for functional assessment in musculoskeletal extremity trauma surgery.

Authors:  Ida L Gitajn; Gerard P Slobogean; Eric R Henderson; Arvind G von Keudell; Mitchel B Harris; John A Scolaro; Nathan N O'Hara; Jonathan T Elliott; Brian W Pogue; Shudong Jiang
Journal:  J Biomed Opt       Date:  2020-08       Impact factor: 3.170

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.